Multimerization of the Receptor Activator of Nuclear Factor-κB Ligand (RANKL) Isoforms and Regulation of Osteoclastogenesis

Tohru Ikeda, Michiyuki Kasai, Junko Suzuki, Hiroyuki Kuroyama, Sachiko Seki, Masanori Utsuyama, Katsuiku Hirokawa

Journal of Biological Chemistry · 2003 · 47 citations · 27 references

DOIFull text

Open access

Concepts

Abstract

The receptor activator of nuclear factor-κB ligand (RANKL), a member of the tumor necrosis factor family, is a transmembrane protein, which is known as an essential initiation factor of osteoclastogenesis. Previously, we identified three RANKL isoforms. RANKL1 was identical to the originally reported RANKL. RANKL2 had a shorter intracellular domain. RANKL3 did not have the intracellular or transmembrane domains and was suggested to act as a soluble form protein. Here, we show that RANKL forms homo- or heteromultimers. NIH3T3 cells transfected with RANKL1 or RANKL2 form mononuclear tartrate-resistant acid phosphatase-positive preosteoclasts in an in vitro osteoclastogenesis assay system. Coexpression of RANKL1 and RANKL2 induces multinucleated osteoclasts. RANKL3 has no effect on the formation of preosteoclasts or osteoclasts but significantly inhibits fusion of preosteoclasts when coexpressed with RANKL1 and RANKL2. These findings imply the presence of multiple multimeric structures of RANKL, which may regulate bone metabolism. The receptor activator of nuclear factor-κB ligand (RANKL), a member of the tumor necrosis factor family, is a transmembrane protein, which is known as an essential initiation factor of osteoclastogenesis. Previously, we identified three RANKL isoforms. RANKL1 was identical to the originally reported RANKL. RANKL2 had a shorter intracellular domain. RANKL3 did not have the intracellular or transmembrane domains and was suggested to act as a soluble form protein. Here, we show that RANKL forms homo- or heteromultimers. NIH3T3 cells transfected with RANKL1 or RANKL2 form mononuclear tartrate-resistant acid phosphatase-positive preosteoclasts in an in vitro osteoclastogenesis assay system. Coexpression of RANKL1 and RANKL2 induces multinucleated osteoclasts. RANKL3 has no effect on the formation of preosteoclasts or osteoclasts but significantly inhibits fusion of preosteoclasts when coexpressed with RANKL1 and RANKL2. These findings imply the presence of multiple multimeric structures of RANKL, which may regulate bone metabolism. The receptor activator of nuclear factor-κB ligand (RANKL 1The abbreviations used are: RANKLRANK legandRANKreceptor activator of nuclear factor-κBOPGosteoprotegerinOPGLOPG ligandODFosteoclast differentiation factorTRANCEtumor necrosis factor-related activation induced cytokineTNFtumor necrosis factorRTreverse transcriptaseEGSethylene glycol bis(succinimidylsuccinate)TRAPtartrare-resistant acid phosphataseCT-Rcalcitonin receptorGFPgreen fluorescent proteinEGFPenhanced GFPDsRedred fluorescent protein. also known as OPGL, ODF, or TRANCE) is a type II TNF-like transmembrane protein, which plays fundamental roles for fusion of preosteoclasts by binding to the receptor, receptor activator of nuclear factor-κB (RANK) (1Nakagawa N. Kinosaki M. Yamaguchi K. Yasuda H. Yano K. Morinaga T. Higashio K. Biochem. Biophys. Res. Commun. 1998; 253: 395-400Crossref PubMed Scopus (628) Google Scholar, 2Hsu H. Lacey D.L. Dunstan C.R. Solovyev I. Colombero A. Timms E. Tan H.-L. Elliott G. Kelley M.J. Sarosi I. Wang L. Xia X.Z. Elliott R. Chiu L. Black T. Scully S. Capparelli C. Morony S. Shimamoto G. Bass M.B. Boyle W.J. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 3540-3545Crossref PubMed Scopus (1428) Google Scholar). Another soluble form receptor-like molecule, osteoprotegerin (OPG), binds to RANKL and inhibits osteoclastogenesis by competitive inhibition of the signaling through the RANKL/RANK system (3Simonet W.S. Lacey D.L. Dunstan C.R. Kelley M. Chang M.-S. Lüthy R. Nguyen H.Q. Wooden S. Bennett L. Boone T. Shimamoto G. DeRose M. Elliott R. Colombero A. Tan H.-L. Trail G. Sullivan J. Davy E. Bucay N. Renshaw-Gegg L. Hughes T.M. Hill D. Pattison W. Campbell P. Sander S. Van G. Tarpley J. Derby P. Lee R. Boyle W.J. Cell. 1997; 89: 309-319Abstract Full Text Full Text PDF PubMed Scopus (4374) Google Scholar, 4Yasuda H. Shima N. Nakagawa N. Mochizuki S. Yano K. Fujise N. Sato Y. Goto M. Yamaguchi K. Kuriyama M. Kanno T. Murakami A. Tsuda E. Morinaga T. Higashio K. Endocrinology. 1998; 139: 1329-1337Crossref PubMed Scopus (965) Google Scholar). Osteoclastogenesis is efficiently reproduced by an in vitro coculture system using macrophages and bone marrow stromal cells (5Udagawa N. Takahashi N. Akatsu T. Sasaki T. Yamaguchi A. Kodama H. Martin J. Suda T. Endocrinology. 1989; 125: 1805-1813Crossref PubMed Scopus (446) Google Scholar, 6Tsukii K. Shima N. Mochizuki S. Yamaguchi K. Kinosaki M. Yano K. Shibata O. Udagawa N. Yasuda H. Suda T. Higashio K. Biochem. Biophys. Res. Commun. 1998; 246: 337-341Crossref PubMed Scopus (221) Google Scholar). In the presence of recombinant RANKL protein, osteoclasts were formed without bone marrow stromal cells (7Lacey D.L. Timms E. Tan H.-L. Kelley M.J. Dunstan C.R. Burgess T. Elliott R. Colombero A. Elliott G. Scully S. Hsu H. Sullivan J. Hawkins N. Davy E. Capparelli A. Eli Y.-X. Qian S. Kaufman I. Sarosi V. Shalhoub G. Senaldi J. Guo J. Delaney C. Boyle W.J. Cell. 1998; 93: 165-1176Abstract Full Text Full Text PDF PubMed Scopus (4656) Google Scholar, 8Yasuda H. Shima N. Nakagawa N. Yamaguchi K. Kinosaki M. Mochizuki S. Tomoyasu A. Yano K. Goto M. Murakami A. Tsuda E. Morinaga T. Higashio K. Udagawa N. Takahashi N. Suda T. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 3597-3600Crossref PubMed Scopus (3592) Google Scholar, 9Lum L. Wong B.R. Josien R. Becherer J.D. Erdjument-Bromage H. Schlöndorff J. Tempst P. Choi Y. Blobel C.P. J. Biol. Chem. 1999; 274: 13613-13618Abstract Full Text Full Text PDF PubMed Scopus (366) Google Scholar). The essential role of the RANKL/RANK system in osteoclastogenesis was confirmed in mice with a disrupted RANKL gene and mice with disruption of the RANK gene, both of which showed severe osteopetrosis (10Kong Y.Y. Yoshida H. Sarosi I. Tan H.-L. Timms E. Capparelli C. Morony S. Oliveira-dos-Santos A.J. Van G. Itie A. Khoo W. Wakeham A. Dunstan C.R. Lacey D.L. Mak T.W. Boyle W.J. Penninger J.M. Nature. 1999; 397: 315-323Crossref PubMed Scopus (2887) Google Scholar, 11Dougall W.C. Glaccum M. Charrier K. Rohrbach K. Brasel K. Smedt T.D. Daro E. Smith J. Tometsko M.E. Maliszewski C.R. Armstrong A. Shen V. Bain S. Cosman D. Anderson D. Morrissey P.J. Peschon J.J. Schuh J. Genes Dev. 1999; 13: 2412-2424Crossref PubMed Scopus (1210) Google Scholar, 12Li J. Sarosi I. Yan X.-Q. Morony S. Capparelli C. Tan H.-L. McCabe S. Elliott R. Scully S. Van G. Kaufman S. Juan S.-C. Sun Y. Tarpley J. Martin L. Christensen K. McCabe J. Kostenuik P. Hsu H. Fletcher F. Dunstan C.R. Lacey D.L. Bolye W.J. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 1566-1571Crossref PubMed Scopus (958) Google Scholar). RANK legand receptor activator of nuclear factor-κB osteoprotegerin OPG ligand osteoclast differentiation factor tumor necrosis factor-related activation induced cytokine tumor necrosis factor reverse transcriptase ethylene glycol bis(succinimidylsuccinate) tartrare-resistant acid phosphatase calcitonin receptor green fluorescent protein enhanced GFP red fluorescent protein. Previously, we identified three RANKL isoforms from mouse cDNA and named them RANKL1, RANKL2, and RANKL3 (13Ikeda T. Kasai M. Utsuyama M. Hirokawa K. Endocrinology. 2000; 142: 1419-1426Crossref Scopus (161) Google Scholar). RANKL1 was identical to the originally reported RANKL. RANKL2 had a shorter intracellular domain. RANKL3 did not have the intracellular or transmembrane domains and was suggested to be a soluble form protein. Previous findings showed that both tumor necrosis factor (TNF)-α and TNF-β formed trimers, and the multimeric structure was essential for expressing the activities of the molecules (14Smith R.A. Baglioni C. J. Biol. Chem. 1987; 262: 6951-6954Abstract Full Text PDF PubMed Google Scholar, 15Jones E.Y. Stuart D.I. Walker N.P. Nature. 1989; 338: 225-228Crossref PubMed Scopus (482) Google Scholar, 16Banner D.W. D'Arcy A. Janes W. Gents R. Schoenfeld H.J. Broger C. Loetscher H. Lesslauer W. Cell. 1993; 73: 431-445Abstract Full Text PDF PubMed Scopus (990) Google Scholar). These findings strongly suggest that another member of this family, RANKL, also forms a multimeric structure. Recently, the crystal structure of the extracellular domain of mouse RANKL was determined, and it was shown to form a trimeric structure (17Ito S. Wakabayashi K. Ubukata O. Hayashi S. Okada F. Hata T. J. Biol. Chem. 2002; 277: 6631-6636Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar, 18Lam J. Nelson C.A. Ross F.P. Teitelbaum S.L. Fremont D.H. J. Clin. Invest. 2001; 108: 971-979Crossref PubMed Scopus (158) Google Scholar). The present study revealed that the mouse RANKL isoforms interact and express different biological activities. Transfection and Selection—For immunoprecipitation and confocal microscopy, the protein-coding region of cDNA for each RANKL isoform was cloned into pEGFP-N2 and pDsRed-N1 vectors (Clontech), both of which express the product of inserted cDNA as a fusion to the N terminus of fluorescent protein, EGFP and DsRed, respectively. For osteoclastogenesis assay, each RANKL isoform was cloned into selectable mammalian expression vector, pMIK HygB (13Ikeda T. Kasai M. Utsuyama M. Hirokawa K. Endocrinology. 2000; 142: 1419-1426Crossref Scopus (161) Google Scholar), pcDNA3.1 (Invitrogen), or pEFBOSbsr (19Hachiya A. Aizawa S. Tanaka M. Takahashi Y. Ida S. Gatanaga H. Hirabayashi Y. Kojima A. Tatsumi M. Oka S. Antimicrob. Agents Chemother. 2001; 45: 495-501Crossref PubMed Scopus (80) Google Scholar). Transfections were performed using the TransFast transfection reagent (Promega). NIH3T3 cells transfected with pMIK HygB-RANKL were cultured in α-minimal essential medium with 10% fetal bovine serum and 250 μg/ml Hygromycin B (Cal-biochem). In some clones expressing each RANKL isoform, pcDNA3.1-RANKL was additionally transfected. The cells were selected and maintained in the medium supplemented with 500 μg/ml Geneticin (Sigma) in addition to the Hygromycin B. To obtain cells expressing RANKL1, RANKL2, and RANKL3, pEFBOSbsr-RANKL3 was further transfected to the cells expressing RANKL1 and RANKL2. Cells were selected and maintained in the medium supplemented with 0.2 μg/ml Blasticidin S hydrochloride (Funakoshi) in addition to the Hygromycin B and Geneticin. The expression of each RANKL isoform was analyzed by reverse transcriptase (RT)-PCR and Northern hybridization. RT-PCR was performed as described previously (13Ikeda T. Kasai M. Utsuyama M. Hirokawa K. Endocrinology. 2000; 142: 1419-1426Crossref Scopus (161) Google Scholar) using forward primers, 5′-CTGAGCTATTCCAGAAGTAGTGAGGAGG-3′, 5′-CTGCAGATATCCAGCACAGTGGCG-3′, and 5′-TCGCAACGGGTTTGCCGCCAGAAC-3′, which recognized downstream from the transcriptional initiation site of pMIK HygB, pcDNA3.1, and pEFBOSbsr, respectively, and a common reverse primer, 5′-TCAGTCTATGTCCTGAACTTTGAAAGCCCC-3′, which recognized the 3′ end of the inserted mouse RANKL cDNA. Northern hybridization was performed as described previously (13Ikeda T. Kasai M. Utsuyama M. Hirokawa K. Endocrinology. 2000; 142: 1419-1426Crossref Scopus (161) Google Scholar). Immunoprecipitation—RANKL-pDsRed and/or RANKL-pEGFP were transfected to NIH3T3 cells plated in 100-mm-type culture dishes. After 48 h, cells were collected and lysed with 1 ml of lysis buffer (Tris-buffered saline (pH 7.1) containing 1% digitonin, 1 mm EDTA, 0.02% NaN3, 1 mm phenylmethanesulfonyl fluoride, 100 μmN-p-tosyl-l-phenylalanine chloromethyl ketone, 10 μm leupeptin, and 10 μg/ml aprotinin), and the supernatants were precleared with Sepharose 4B coupling with 100 μg of rabbit immunoglobulins and incubated with 40 μg of rabbit anti-DsRed-peptide antibody (Clontech, catalog number 8370) cross-linked to immobilized Protein G (Pierce, catalog number 45210) for 72 h. The immune complexes were washed with lysis buffer three times and eluted with 100 μl of elution buffer (1% digitonin, 50 mm glycin-HCl (pH 3.0), 150 mm NaCl, 0.02% NaN3). The eluant was adjusted to pH 7.0 with 1 m Tris-HCl (pH 9.0). Samples were separated by 10% SDS-PAGE and transferred electrophoretically onto nitrocellulose membranes (Schleicher & Schuell). Immunoblotting was performed using the rabbit anti-DsRed-peptide antibody or a mouse anti-GFP monoclonal antibody (Clontech, catalog number 8371). Immunoreactive proteins were visualized using the ECL Western blotting detection kit (Amersham Pharmacia Biotech). Cross-linking of Recombinant RANKL3 Protein—Five μg of recombinant mouse RANKL3 (13Ikeda T. Kasai M. Utsuyama M. Hirokawa K. Endocrinology. 2000; 142: 1419-1426Crossref Scopus (161) Google Scholar) was treated with 1.2 mg/ml ethylene glycol bis(succinimidylsuccinate) (EGS) (Pierce) at 4 °C for 2 h. Part of the cross-linked samples was cleaved using 1 m hydroxylamine hydrochloride (Pierce), pH 8.5, at 37 °C for 4 h. The samples were separated by 10% SDS-PAGE and visualized by Coomassie Brilliant Blue staining. Confocal Microscopy—RANKL-pDsRed and/or RANKL-pEGFP were transfected to NIH3T3 cells plated on 35-mm glass-bottom dishes (Iwaki Glass). After 48 h, they were viewed before or after fixation with 3.8% formaldehyde in phosphate-buffered saline using an LSM 510 laser scanning confocal microscope (Zeiss) equipped with a ×63 water immersion objective. EGFP was examined using the 488-nm line of the argon-krypton laser and a set of the 488-nm main splitter and the 505–530-nm band pass emission. DsRed was examined using the 543-nm line of the helium-neon laser and a set of the 488/543-nm main splitter HFT and the 560-nm long pass emission. Osteoclastogenesis Assays and Cytochemical Staining—Mouse bone marrow macrophages were prepared from femora and tibiae of 5-week-old female ddy mice as described previously (20Shioi A. Ross F.P. Teitelbaum S.L. Calcif. Tissue Int. 1994; 55: 387-394Crossref PubMed Scopus (34) Google Scholar, 21Inoue M. Namba N. Chappel J. Teitelbaum S.L. Ross F.P. Mol. Endocrinol. 1998; 12: 1955-1962Crossref PubMed Google Scholar). Using 48-well plates, the bone marrow macrophages (1.5 × 105 cells/well) were cocultured with NIH3T3 cells expressing RANKL isoform(s) (1.5 × 104 cells/well) in 0.25 ml/well of α-minimal essential medium supplemented with 10% fetal bovine serum, 30 ng/ml macrophage colony-stimulating factor, 1 × 10-8m of 1α,25-dihydroxyvitamin D3, and 1 × 10-7m of dexamethasone. After 5–10 days of culture, cells were fixed with 4% formaldehyde in phosphate-buffered saline (-) for 10 and for 2 acid phosphatase was with m buffer (pH containing mg/ml mg/ml red and 50 mm was using the was in with for in and In of were on 48-well plates, and were performed on them (5Udagawa N. Takahashi N. Akatsu T. Sasaki T. Yamaguchi A. Kodama H. Martin J. Suda T. Endocrinology. 1989; 125: 1805-1813Crossref PubMed Scopus (446) Google Scholar). days after the culture the were in 4 m for h, with and with The of was using the in the of a and the of with to the with and without were H. R. T. E. Sato T. M. K. N. T. Calcif. Tissue Int. 1993; PubMed Scopus Google Scholar). The was using the were treated with in for with phosphate-buffered and treated with bovine serum at 4 °C antibody calcitonin catalog number or the antibody with the was on the and incubated at 4 °C After with phosphate-buffered was performed using the system of RANKL of RANKL1, RANKL2, and RANKL3 with a of EGFP at the terminus and RANKL1, RANKL2, and RANKL3 with a of DsRed at the terminus were transfected to NIH3T3 cells and for immunoprecipitation and Western The expression of transfected and was in with the antibody The expression of and 4 and was with the of with the antibody was confirmed using the of and was In the with and and with the of protein was with the antibody of was also in the with and In the with and in addition to and no protein was 4 and To the of RANKL3 protein, recombinant RANKL3 protein was cross-linked with and visualized by Coomassie Brilliant Blue staining. Recombinant RANKL3 treated with revealed a and a of which was cleaved by hydroxylamine hydrochloride to a and were also using as the and J. In intracellular of three RANKL isoforms was analyzed by of the protein using a confocal RANKL1 and RANKL2 were as the region of the but RANKL3 was as the cells In the cells with and both and were In the cells with and both and were but the was not as as and of and and of and were but in some of the of the were and of RANKL on NIH3T3 cells expressing each RANKL isoform or different RANKL and clones for each were used as stromal cells for in vitro osteoclastogenesis In addition to macrophage colony-stimulating factor, 1α,25-dihydroxyvitamin and were further supplemented with the culture medium to the expression of OPG of both NIH3T3 cells and macrophages NIH3T3 cells expressing RANKL1 or RANKL2 induced mononuclear but multinucleated osteoclasts were formed a and NIH3T3 cells expressing RANKL3 did not cells NIH3T3 cells of RANKL1 and RANKL2 induced multinucleated osteoclasts. of the culture was with the multinucleated and mononuclear preosteoclasts were at 1 after the coculture NIH3T3 cells with of RANKL1 and RANKL3 and of RANKL2 and RANKL3 induced mononuclear but the expression of RANKL3 did not the number significantly and and To the of RANKL1 and RANKL2 in the is to multinucleated NIH3T3 cells expressing RANKL1 were with the cells expressing RANKL2 and used for of cells and cells induced mononuclear preosteoclasts but did not multinucleated osteoclasts and is also a that expression of the RANKL isoform the formation of multinucleated osteoclasts. To or was additionally transfected to cells the expression of RANKL1 or RANKL2, respectively. expression of RANKL1 and expression of RANKL2 induced a multinucleated osteoclasts h, and not The of RANKL1 in NIH3T3 cells used in the shown in and h, shown in Previously, we reported that the analyzed and a bone marrow stromal line the three RANKL isoforms (13Ikeda T. Kasai M. Utsuyama M. Hirokawa K. Endocrinology. 2000; 142: 1419-1426Crossref Scopus (161) Google Scholar). we further the expression of RANKL3 in the NIH3T3 cells expressing RANKL1 and RANKL2 and expression of RANKL3 significantly the formation of and mononuclear preosteoclasts were a and and The using NIH3T3 cells expressing RANKL1 and RANKL2 formed on the the of the using NIH3T3 cells expressing RANKL1, RANKL2, and RANKL3, were also but the was The of the on the in the using NIH3T3 cells expressing RANKL1, RANKL2, and RANKL3 was significantly as with that in the expressing RANKL1 and RANKL2 To further the effect of RANKL3 on the of the presence of was analyzed by In the of bone marrow macrophages and NIH3T3 cells expressing RANKL1, RANKL2, and RANKL3, were in both mononuclear and multinucleated cells as reported previously in of mouse cells and cells (5Udagawa N. Takahashi N. Akatsu T. Sasaki T. Yamaguchi A. Kodama H. Martin J. Suda T. Endocrinology. 1989; 125: 1805-1813Crossref PubMed Scopus (446) Google Scholar). In the analyzed with the antibody with the no was RANKL, a member of had to form multimeric structures to and of and showed that the extracellular domain of RANKL forms trimeric structures (17Ito S. Wakabayashi K. Ubukata O. Hayashi S. Okada F. Hata T. J. Biol. Chem. 2002; 277: 6631-6636Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar, 18Lam J. Nelson C.A. Ross F.P. Teitelbaum S.L. Fremont D.H. J. Clin. Invest. 2001; 108: 971-979Crossref PubMed Scopus (158) Google Scholar, D. W.J. G. K. J. T. C. E. S. J. B. Protein 2000; PubMed Scopus Google Scholar). the we previously identified three isoforms of mouse RANKL cDNA. was identical to the originally reported RANKL, another had a shorter intracellular and the the intracellular and transmembrane which were named RANKL1, RANKL2, and RANKL3, (13Ikeda T. Kasai M. Utsuyama M. Hirokawa K. Endocrinology. 2000; 142: 1419-1426Crossref Scopus (161) Google Scholar). that RANKL isoforms Here, we showed of RANKL1 with RANKL1 or RANKL2 by immunoprecipitation using the proteins with EGFP or DsRed RANKL3 did not with RANKL1 or RANKL2. RANKL3 has the extracellular domain of RANKL, RANKL3 may interact with RANKL isoforms as reported previously (17Ito S. Wakabayashi K. Ubukata O. Hayashi S. Okada F. Hata T. J. Biol. Chem. 2002; 277: 6631-6636Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar, 18Lam J. Nelson C.A. Ross F.P. Teitelbaum S.L. Fremont D.H. J. Clin. Invest. 2001; 108: 971-979Crossref PubMed Scopus (158) Google Scholar, D. W.J. G. K. J. T. C. E. S. J. B. Protein 2000; PubMed Scopus Google Scholar). we showed that recombinant RANKL3 without the and forms a by a study it was suggested that RANKL3 also with RANKL isoforms at the extracellular domain and forms homo- or we not have for of RANKL3 to RANKL1 and RANKL2. In the findings suggest that the proteins not the of RANKL, and RANKL1 with RANKL1 and RANKL2. of RANKL1 with RANKL1 or RANKL2 was by the was suggested to be the was not when cells were lysed with the lysis buffer containing and was when of the digitonin, was used in of Kasai and T. of RANKL3 with RANKL1 or RANKL2 in the transfected cells that the of RANKL3 is RANKL1 or RANKL2, and this be the for the of of RANKL3 was different from of RANKL1 and RANKL2 and the of RANKL3 in the region that RANKL3 was not and and in the be in the using NIH3T3 cells expressing RANKL3, preosteoclasts osteoclasts were formed recombinant RANKL3 protein induced osteoclasts when to bone marrow is also a that RANKL3 is as a soluble form protein, but it in the culture and the is not to preosteoclasts or osteoclasts. Coexpression of RANKL1 and RANKL2 enhanced the formation of multinucleated but a of cells and cells did These findings suggest that the of both RANKL1 and RANKL2 in the cells is for the formation of multinucleated osteoclasts. shown in 1 and RANKL isoforms interact with and the is suggested to form of RANKL1 and RANKL2. of RANKL1 or RANKL2 also induced multinucleated osteoclasts. These suggest that of RANKL1 and RANKL2 fusion of preosteoclasts in this assay but they not essential to fusion of and also suggest that expression of RANKL1 or RANKL2 is for fusion formation of described RANKL3 induced preosteoclasts and the expression of RANKL3 to RANKL1 or RANKL2 did not the formation of preosteoclasts and and the expression of RANKL3 significantly the of multinucleated cells when coexpressed with RANKL1 and RANKL2. These suggest that RANKL3 inhibits fusion of preosteoclasts when coexpressed with RANKL1 and RANKL2. the of RANKL the to the fusion of preosteoclasts by the expression of RANKL3 be with intracellular of RANKL3 with RANKL1 and/or RANKL2. shown in the expression of was in preosteoclasts and osteoclasts induced by NIH3T3 cells expressing RANKL1, RANKL2, and These findings that the expression of RANKL3 not of preosteoclasts and osteoclasts but inhibits fusion of The findings in the present study strongly suggest that multiple multimeric structures of RANKL present and regulate bone metabolism. with selectable of the expression of each RANKL isoform may as of bone metabolism. RANKL has multiple differentiation and fusion of osteoclast cells and activation and of osteoclasts K. Wong B. S. Choi Y. J. 1998; PubMed Scopus Google Scholar, Qian Y.-X. Kaufman S. Van G. C. Kelley M. Hsu H. Boyle W.J. Dunstan C.R. S. Lacey D.L. J. Biol. 1999; PubMed Scopus Google Scholar, E. S. T. N. K. Udagawa N. T. Takahashi N. Suda T. J. 1999; Google Scholar, D.L. Tan H.-L. J. Kaufman S. Van G. W. A. Scully S. Fletcher F. Juan T. Kelley M. Burgess Boyle W.J. A.J. J. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). of multiple may be by the multiple multimeric structures of RANKL. N. Udagawa for and M. Tatsumi for pEFBOSbsr vector, and H. and H. for to also N. for

References

27